Business
The molecular diagnostics market is a fast-growing portion of the in vitro (test tube-based, controlled environment) diagnostics market.
Co-Diagnostics, Inc.: Revenue declined 84.1% to $622K from $3.915M. Net loss widened to $46.9M from $37.64M. Free cash flow outflow narrowed to $29.84M from $29.9M. Operating margin contracted 703508 bps to -8058.83%. Co-Diagnostics, Inc.'s annual comparison also shows the manipulation screen is flagged and should be investigated as a warning rather than treated as proof; the balance-sheet screen falls in the distress range and requires business-model context; the earnings-quality screen is distress.
The read at a glance✓ Audited against SEC data
- Growth — Revenue declined 84.1% to $622K from $3.915MWatch
- Profitability — Net loss widened to $46.9M from $37.64MWatch
- Cash flow — Free cash flow outflow narrowed to $29.84M from $29.9MOK
- Margins — Operating margin contracted 703508 bps to -8058.83%Watch
- Accounting — Going-concern warningWatch
- Insiders — 0 purchases and 0 salesNote
Where the revenue comes from
Fiscal 2025, as Co-Diagnostics, Inc. reports it. History and quarterly detail are in the app.
- Product$418K
- Grant$204K
Leadership changes
From Co-Diagnostics, Inc.'s own filings, the day they're filed.
- Richard Abbott · President · appointmenteff. 2024-03-15
Latest filings
- 8-K · Company announcement2026-08-13
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-07-31
- 8-K · Company announcement2026-07-27
- DEF 14A · Annual proxy (pay & governance)2026-07-21
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Co-Diagnostics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.